Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Entero Therapeutics (ENTO) just unveiled an announcement.
Entero Therapeutics, Inc. has announced a strategic shift in their executive team, with Dr. Jack Syage transitioning from Chief Operating Officer to Chief Scientific Officer, while maintaining his role as President. This move, effective immediately, comes without changes to his compensation and signifies a realignment of leadership roles within the company to better leverage Dr. Syage’s expertise.
Learn more about ENTO stock on TipRanks’ Stock Analysis page.